- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00183794
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
This study is for patients with advanced ovarian cancer that has reappeared after treatment with conventional therapy. The purpose of this study is to determine if the combination of docetaxel and gemcitabine will be effective in reducing or eliminating the tumor(s) in patients with ovarian cancer.
Docetaxel is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancer; gemcitabine is approved by the FDA for the treatment of pancreatic and lung cancer. Neither docetaxel nor gemcitabine are approved for the treatment of ovarian cancer. Both drugs have been shown to decrease the size of ovarian cancer tumors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
1. To determine the response rate, time to progression and survival (secondary) of the combination of docetaxel and gemcitabine administered on a weekly basis to patients with platinum-resistant ovarian cancer
Secondary Objective:
- To determine the toxicity of this combination regimen in patients with platinum-resistant ovarian cancer
- To evaluate the toxicity and safety profile of a short course (one dose) of premedication with steroids to patients receiving weekly gemcitabine and docetaxel
OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Treatment repeats every 21 days until PD, unacceptable toxicity, or patient's withdrawal.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Norris Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven diagnosis of epithelial ovarian ca
- Must have platinum-resistant disease. (Defined as progression during the most recent platinum-based chemotx or relapse < 6 months after the most recent platinum-based chemotx regimen.)
- Measurable or evaluable disease. (Patients whose dz is manifested only as an elevated CA-125 [greater than or equal to 100] are eligible. If an elevated CA-125 is the only manifestation of dz, it must be confirmed on 2 separate times, at least 2 weeks apart. Patients with positive cytology only are not eligible.)
- Greater than or equal to 18 years of age
- GOG performance status less than or equal to 2
- AGC/ANC greater than or equal to 1.5; platelets greater than or equal to 100,000; hemoglobin (Hgb) greater than or equal to 8.0.
- Creatinine less than or equal to 2.0
- Total bilirubin less than or equal to upper limit of normal (uln)
- SGOT and/or SGPT less than or equal to 2.5 x uln if alkaline phosphatase less than or equal to uln, or alkaline phosphatase less than or equal to 4 x uln if transaminases are less than or equal to uln. (If both SGOT/SGPT >1.5 x uln and alkaline phosphatase > 2.5 x uln, patient is not eligible.)
- Fully recovered from acute toxicities secondary to prior treatment (tx)
- Signed informed consent
Exclusion Criteria:
- Prior treatment with gemcitabine or docetaxel
- Underlying medical, psychiatric, or social conditions that would preclude patient from receiving treatment
- Peripheral neuropathy greater than or equal to Grade 2
- No prior tx with cisplatin or carboplatin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
|
Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response Type: CR, PR, SD or PD
Time Frame: 6 months after enrollment of last participant
|
Tumor response will be based on the RECIST v1.0 criteria.
CR (complete response)= disappearance of all target lesions, PR (partial response)= greater or equal to 30% decrease in sum of longest diameter of target lesions, SD (stable disease)= <30% decrease or <20% increase, PD (progressive disease)= greater or equal to 20% increase in longest diameter of target lesions.
For patients with an elevated CA-125 as the only evidence of disease, a PR was defined as a decrease of 50% or more lasting at least 8 weeks (Rustin et al.
JCO 14:1545-51, 1996).
Disease assessment performed every 2 cycles (1 cycle = 21 days).
Responders included CR and PR.
|
6 months after enrollment of last participant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Time to Progression (Months)
Time Frame: 6 months after enrollment of last patient
|
Defined as the time from first day of treatment to the first observation of disease progression or death due to any cause.
If a patient has not progressed or died, progression-free survival is censored at the time of last follow-up.
Progression based on RECIST v1.0 criteria for measurable disease, and on CA-125 for patients with an elevated CA-125 as the only evidence of disease (Rustin et al.
JCO 14:1545-51, 1996)
|
6 months after enrollment of last patient
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Peritoneal Diseases
- Digestive System Neoplasms
- Abdominal Neoplasms
- Carcinoma
- Peritoneal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Gemcitabine
- Docetaxel
Other Study ID Numbers
- 5GYN-02-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Neoplasms
-
University of Michigan Rogel Cancer CenterCompletedOvarian, Fallopian Tube, and Primary Peritoneal CancerUnited States
-
AstraZenecaCompletedOvarian, Fallopian Tube, Peritoneal Cancer, P53 MutationUnited States, Canada, Netherlands
-
Association Francaise de ChirurgieCompletedCarcinomatosis, PeritonealFrance
-
Hasselt UniversityZiekenhuis Oost-LimburgUnknownColorectal Peritoneal CarcinomatosisBelgium
-
M.D. Anderson Cancer CenterCompletedPeritoneal CancerUnited States
-
University of California, IrvineRecruitingPeritoneal Carcinomatosis | Gastrointestinal Peritoneal CarcinomatosisUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedPatients With Gastric Peritoneal CarcinomatosisFrance
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerUnited States, Australia, France
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnOvarian, Fallopian Tube and Peritoneal CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Gateway for Cancer ResearchActive, not recruitingPrimary Peritoneal Cancer | Fallopian Tube | Epithelial OvarianUnited States
Clinical Trials on Docetaxel and Gemcitabine
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
SanofiCompletedNon-small Cell Lung CancerItaly
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral CancerUnited States, Puerto Rico, South Africa
-
Spanish Lung Cancer GroupTerminatedNon Small Cell Lung Cancer | BRCA1 MutationSpain
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedPancreatic CancerUnited States
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Recruiting
-
SanofiCompletedCarcinoma, Non-Small-Cell LungItaly
-
Shanghai Jiao Tong University School of MedicineShanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... and other collaboratorsRecruitingRecurrent Non-small Cell Lung CancerChina
-
Medical University of South CarolinaNovartisCompleted